Cellino and Matricelf Collaborate to Scale iPSC-Derived Treatments for Spinal Cord Injury (SCI)
Cellino successfully manufactures and delivers autologous iPSC lines from four donors to Matricelf for groundbreaking neural tissue engineering.
Matricelf transformed Cellino-generated iPSCs into functional neural tissues with synchronized electrical activity.
CAMBRIDGE, Mass. – Cellino and Matricelf (TASE: MTLF) announced a collaboration to accelerate the global biomanufacturing of personalized spinal cord injury treatments using Cellino’s Nebula™ technology combined with Matricelf’s breakthrough regenerative approach. This collaboration combines Cellino’s automated iPSC manufacturing with Matricelf’s double autologous 3D differentiation process, paving the way for scalable, patient-specific regenerative therapies. [Read more…]
Cardiac Stem Cell Therapies for Heart Failure Treatment
Human life is dependent upon the heart’s ability to pump forcefully and frequently enough, but heart failure signs can disturb its normal function. Most humans cannot live more than four minutes without a heartbeat or continuous blood-flow. At that time, brain cells begin to die because they lack adequately oxygenated blood-flow.
The human adult body requires, on average, 5.0 liters of re-circulated blood per minute. In the cardiology field, this metric is called the “Cardiac Output,” which is calculated as “Stroke Volume (SV)” x “Heart Rate (HR).” Another key metric is a patient’s “Ejection-Fraction (EF %).” A patient’s EF tells a cardiologist and other physicians if his or her heart is functioning normally or “low normally.” It is a measurement of one’s heart contraction, with a normal EF range being 55-70%. [Read more…]
Garuda Therapeutics Closes $50 Million Series A-1 Financing to Advance Off-the-Shelf Blood Stem Cell Therapies
New funding will accelerate Garuda’s rapid growth and fund development of off-the-shelf hematopoietic stem cell (HSC) therapies for a multitude of severe and life-threatening diseases
CAMBRIDGE, Mass., March 04, 2025 — Garuda Therapeutics (Garuda), a biotechnology company creating off-the-shelf, HSC therapies for a multitude of blood disorders, today announced the successful completion of an approximately $50 million Series A-1 funding round. Investors included OrbiMed, Northpond Ventures and Cormorant Asset Management, with new strategic investment from Kyowa Kirin Co., Ltd., a Japan-based Global Specialty Pharmaceutical Company. [Read more…]
Coeptis Therapeutics to Pursue Phase 2 Program Using Allogeneic Cord-Blood Derived NK Cell Therapy
Novel NK cell therapy approach is designed to bolster and replenish the immune system during severe viral infection, which can severely reduce immune cells leading to hospitalization and death
DVX201 is the world’s first-ever allogeneic, cord-blood derived NK cell therapy generated from pooled donor CD34+ hematopoietic stem and progenitor cells (HSPC) cells.
WEXFORD, PA, Feb 7, 2024 — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing innovative cell therapy platforms for cancer and infectious diseases, announced plans to pursue DVX201, its proprietary allogeneic stem cell expansion and directed differentiation platform of unmodified natural killer (NK) cell therapy, as an antiviral treatment addressing various respiratory viral infections that lead to hospitalization, including the “tripledemic” of influenza, COVID-19 and respiratory syncytial virus (RSV). [Read more…]
- « Previous Page
- 1
- …
- 58
- 59
- 60
- 61
- 62
- …
- 334
- Next Page »